1. Poland Stocks

  2. •

    Health technology

  3. •

    Medical specialties
PZ Cormay S.A.

PZ Cormay S.A.

GGPW:CRM
0.50
PLN
+0.00
(+0.40%)
49.18MMarket Cap
PZ Cormay S.A.
GPW:CRM
(Warsaw Stock Exchange)

Recent

price

0.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
PLN
2.3
2.75
3.01
2.88
3.11
1.11
1.29
1.18
0.89
0.81
0.77
1.04
0.98
0.98
1.04
1.16
- -
Revenue per Share
0.23
0.42
0.44
0.05
-1.33
-0.61
-0.17
-0.03
-0.32
-0.48
-0.15
0.02
-0.08
-0.05
-0.06
-0.05
- -
Basic EPS, GAAP
-0.52
-0.85
-0.37
-0.49
0.03
-0.26
-0.24
-0.01
-0.05
-0.09
-0.11
-0.1
-0.2
-0.1
-0.04
-0.03
- -
Free Cash Flow per Basic Share
- -
0.02
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
2.43
3.22
4.93
4.45
2.74
1.74
1.68
1.67
1.33
0.86
0.74
0.77
0.72
0.66
0.59
0.55
0.52
Book Value per Share
2.24
2.1
3.94
3.49
2.45
0.94
0.7
0.86
0.73
0.7
0.57
0.58
0.48
0.4
0.34
0.29
0.26
Tangible Book Value per Share
27
33
35
35
32
40
64
65
78
84
84
82
87
84
88
83
85
Basic Weighted Avg Shares
62
90
105
101
99
45
82
78
70
68
65
85
85
82
92
96
- -
Sales/Revenue/Turnover
8.23
14.18
13.02
3.55
-30.75
-16.39
-6.75
-9.62
-34.84
-53.55
-7.32
1.16
-3.29
-5.31
-1.73
-2.2
- -
Operating Margin (%)
1
3
4
4
5
4
4
5
5
4
4
4
5
5
6
6
- -
Depreciation Expense
6
14
15
2
-42
-25
-11
-2
-25
-41
-13
2
-7
-5
-5
-4
- -
Net Income, GAAP
0.99
- -
0.42
2.76
- -
- -
- -
- -
- -
- -
- -
4.5
- -
- -
- -
- -
- -
Effective Tax Rate (%)
9.9
15.23
14.58
1.79
-42.77
-54.68
-13.36
-2.6
-35.79
-59.25
-19.4
1.93
-8.16
-5.51
-5.75
-4.32
- -
Profit Margin (%)
49
60
132
88
51
43
16
12
58
46
39
34
23
14
10
8
7
Working Capital
2
8
11
10
14
8
1
1
1
1
3
3
3
4
4
7
8
LT Debt
66
107
192
213
168
169
146
136
119
74
63
65
61
56
50
46
45
Total Equity
8.8
- -
8.17
1.54
- -
- -
- -
- -
- -
- -
- -
-0.09
- -
- -
- -
- -
- -
Return on Invested Capital (%)
10.7
- -
9.19
-0.29
- -
- -
- -
- -
- -
- -
- -
2.97
- -
- -
- -
- -
- -
Return on Capital (%)
11.22
15.7
10.96
1.1
-33.67
-23.82
-10.14
-1.72
-20.76
-44.08
-18.82
2.58
-11.11
-7.81
-10.05
-8.72
- -
Return on Common Equity (%)

Capital Structure

PLN

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
2
3
3
LT Borrowings
- -
- -
- -
LT Finance Leases
4
7
8
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
84
84
84
Market Capitalization
42
32
49

Working Capital

PLN

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
37
41
40
Cash, Cash Equivalents & STI
1
5
2
Accounts Receivable, Net
17
13
18
Inventories
16
18
18
Total Current Liabilities
29
33
34
Payables & Accruals
- -
- -
- -
ST Debt
2
3
3
Deferred Revenue
- -
- -
- -

Growth Rates

PLN

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-11.48%
-5.93%
-7.21%
Free Cash Flow
34.17%
-8.4%
-34.95%
Net Income, GAAP
31.42%
-135.69%
-20.98%
Sales/Revenue/Turnover
10.39%
8.68%
5.11%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

PLN

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
22
22
23
25
92
2025
23
- -
25
25
96
2026
23
- -
- -
- -
- -

Quarterly Earnings Per Share

PLN

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
-0.04
-0.02
- -
-0.06
2025
0.01
- -
- -
-0.02
-0.05
2026
-0.03
- -
- -
- -
- -

Quarterly Dividends Per Share

PLN

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
PZ Cormay S.A. manufactures and distributes in vitro diagnostic (IVD) reagents and laboratory equipment for clinical and veterinary applications. The company produces a comprehensive range of diagnostic tests including clinical chemistry reagents such as enzymatic glucose, total bilirubin, and cholesterol kits; hematology solutions encompassing 3-Diff and 5-Diff systems like Mythic 22 OT, Mythic 22 AL, Mythic 60, Mythic 70, and Mythic 3CRP analyzers; immunochemistry products; coagulation and electrophoresis reagents; urinalysis test strips; parasitology tests like MINI-SYSTEM PARAGREEN; blood grouping serology; molecular biology tools including RT-PCR systems and nucleic acid isolation kits; general analytics; and vacuum blood collection systems, offered under brands such as Orphée and Diesse; it also distributes analyzers from partners like SNIBE, MINDRAY, and AliveDX, alongside cleaning liquids, controls, and calibrators. Founded in 1985 and headquartered at Ursynów Business Park, 303 Puławska Street, 02-785 Warsaw, Poland, with prior operations in Łomianki, PZ Cormay serves small and mid-sized laboratories, clinics, and hospitals in over 120 countries worldwide through a global network of distributors; its Swiss subsidiary Orphee S.A. enhances hematology technology integration. Recent developments include a July 2024 distribution agreement with AliveDx Suisse S.A. to commercialize the MosaiQ multiplexing immunoassay platform in Poland; a new partnership with Randox for RIQAS external quality control services; launch of the Cormay Diagnostics group brand in 2021; strong sales growth reported in early 2025 with rising profitability; and participation in international events like Medlab Middle East 2025 supported by funding from Lubelska Agencja Wspierania Przedsiębiorczości; the company marked its 40th anniversary in 2025, highlighting ongoing R&D expansion and adherence to ISO 13485 standards.